Occam Places Brian Piekos as CFO of Elicio Therapeutics
Elicio Therapeutics (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, using its proprietary lymph node-targeting Amphiphile technology. Occam placed Brian Piekos as the company's Chief Financial Officer, in parallel with the closing of Elicio's previously announced merger with Angion Biomedica Corp.
Brian brings well-honed operational discipline and capital markets wisdom to the party. Most recently, Brian served as CFO of Gemini Therapeutics. Prior to joining Gemini, Brian was CFO at AMAG Pharmaceuticals upon the company’s sale in November 2021. Before that, Brian held leadership roles in Corporate Finance, Tax and Treasury at Cubist Pharmaceuticals. He began his career as a healthcare investment banker at Needham & Company and Leerink Partners.
Elicio is a longstanding client of Occam's. Previous placements include Head of R&D and Chief Medical Officer Chris Haqq, Chief Business Officer Annette Matthies, and Board Director Daphne Karydas.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.